HCV and the hepatic lipid pathway as a potential treatment target
Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major foc...
Gespeichert in:
| Veröffentlicht in: | Journal of hepatology 2011-12, Vol.55 (6), p.1428-1440 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1440 |
|---|---|
| container_issue | 6 |
| container_start_page | 1428 |
| container_title | Journal of hepatology |
| container_volume | 55 |
| creator | Bassendine, Margaret F Sheridan, David A Felmlee, Daniel J Bridge, Simon H Toms, Geoffrey L Neely, R. Dermot G |
| description | Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus–host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3] . One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy. |
| doi_str_mv | 10.1016/j.jhep.2011.06.004 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_905674350</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0168827811004922</els_id><sourcerecordid>905674350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c550t-86c3c6c8313f689b24688b505c47fc0d3c6e40463b5f89512ab7e7e25bf8d0e83</originalsourceid><addsrcrecordid>eNp9kUGL1DAYhoMo7rj6BzxILuKp9UuapCmIsAzqCgt7WPUa0vSrk9ppa5JxmX9vyowKHvaUhDzvm_B8hLxkUDJg6u1QDjtcSg6MlaBKAPGIbJgCKEAJ9phsMqQLzWt9QZ7FOABABY14Si44q5lWSm7I1fX2G7VTR9MOaW6zyTs6-sV3NO939_ZIbaSWLnPCKXk70hTQpn0-0GTDd0zPyZPejhFfnNdL8vXjhy_b6-Lm9tPn7dVN4aSEVGjlKqecrljVK920XCitWwnSibp30OVLFCBU1cpeN5Jx29ZYI5dtrztAXV2SN6feJcw_DxiT2fvocBzthPMhmgakqkUlIZP8RLowxxiwN0vwexuOhoFZzZnBrObMas6AMtlcDr061x_aPXZ_I39UZeD1GbDR2bEPdnI-_uNEzbVq1qJ3Jw6zjF8eg4nO4-Sw8wFdMt3sH_7H-__ibvSTzy_-wCPGYT6EKWs2zERuwNytM15HzFhON5xXvwGgAZ9a</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>905674350</pqid></control><display><type>article</type><title>HCV and the hepatic lipid pathway as a potential treatment target</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Bassendine, Margaret F ; Sheridan, David A ; Felmlee, Daniel J ; Bridge, Simon H ; Toms, Geoffrey L ; Neely, R. Dermot G</creator><creatorcontrib>Bassendine, Margaret F ; Sheridan, David A ; Felmlee, Daniel J ; Bridge, Simon H ; Toms, Geoffrey L ; Neely, R. Dermot G</creatorcontrib><description>Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus–host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3] . One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.</description><identifier>ISSN: 0168-8278</identifier><identifier>EISSN: 1600-0641</identifier><identifier>DOI: 10.1016/j.jhep.2011.06.004</identifier><identifier>PMID: 21718665</identifier><identifier>CODEN: JOHEEC</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Apolipoproteins A - metabolism ; Apolipoproteins B - metabolism ; Apolipoproteins E - metabolism ; Biological and medical sciences ; Cholesterol ; Chronic ; Chylomicrons - metabolism ; Gastroenterology and Hepatology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepacivirus - metabolism ; Hepacivirus - pathogenicity ; Hepatitis C ; Hepatitis C - metabolism ; Hepatitis C - therapy ; Hepatitis C - virology ; Human viral diseases ; Humans ; Hypolipidemic Agents - therapeutic use ; Infectious diseases ; Lipid Metabolism - drug effects ; Lipoproteins ; Lipoproteins, VLDL - metabolism ; Liver - metabolism ; Medical sciences ; Metabolic Networks and Pathways ; Models, Biological ; Pharmacology. Drug treatments ; Triglycerides ; Viral diseases ; Viral hepatitis ; VLDL</subject><ispartof>Journal of hepatology, 2011-12, Vol.55 (6), p.1428-1440</ispartof><rights>European Association for the Study of the Liver</rights><rights>2011 European Association for the Study of the Liver</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c550t-86c3c6c8313f689b24688b505c47fc0d3c6e40463b5f89512ab7e7e25bf8d0e83</citedby><cites>FETCH-LOGICAL-c550t-86c3c6c8313f689b24688b505c47fc0d3c6e40463b5f89512ab7e7e25bf8d0e83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0168827811004922$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24728694$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21718665$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bassendine, Margaret F</creatorcontrib><creatorcontrib>Sheridan, David A</creatorcontrib><creatorcontrib>Felmlee, Daniel J</creatorcontrib><creatorcontrib>Bridge, Simon H</creatorcontrib><creatorcontrib>Toms, Geoffrey L</creatorcontrib><creatorcontrib>Neely, R. Dermot G</creatorcontrib><title>HCV and the hepatic lipid pathway as a potential treatment target</title><title>Journal of hepatology</title><addtitle>J Hepatol</addtitle><description>Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus–host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3] . One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.</description><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Apolipoproteins A - metabolism</subject><subject>Apolipoproteins B - metabolism</subject><subject>Apolipoproteins E - metabolism</subject><subject>Biological and medical sciences</subject><subject>Cholesterol</subject><subject>Chronic</subject><subject>Chylomicrons - metabolism</subject><subject>Gastroenterology and Hepatology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepacivirus - metabolism</subject><subject>Hepacivirus - pathogenicity</subject><subject>Hepatitis C</subject><subject>Hepatitis C - metabolism</subject><subject>Hepatitis C - therapy</subject><subject>Hepatitis C - virology</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Hypolipidemic Agents - therapeutic use</subject><subject>Infectious diseases</subject><subject>Lipid Metabolism - drug effects</subject><subject>Lipoproteins</subject><subject>Lipoproteins, VLDL - metabolism</subject><subject>Liver - metabolism</subject><subject>Medical sciences</subject><subject>Metabolic Networks and Pathways</subject><subject>Models, Biological</subject><subject>Pharmacology. Drug treatments</subject><subject>Triglycerides</subject><subject>Viral diseases</subject><subject>Viral hepatitis</subject><subject>VLDL</subject><issn>0168-8278</issn><issn>1600-0641</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kUGL1DAYhoMo7rj6BzxILuKp9UuapCmIsAzqCgt7WPUa0vSrk9ppa5JxmX9vyowKHvaUhDzvm_B8hLxkUDJg6u1QDjtcSg6MlaBKAPGIbJgCKEAJ9phsMqQLzWt9QZ7FOABABY14Si44q5lWSm7I1fX2G7VTR9MOaW6zyTs6-sV3NO939_ZIbaSWLnPCKXk70hTQpn0-0GTDd0zPyZPejhFfnNdL8vXjhy_b6-Lm9tPn7dVN4aSEVGjlKqecrljVK920XCitWwnSibp30OVLFCBU1cpeN5Jx29ZYI5dtrztAXV2SN6feJcw_DxiT2fvocBzthPMhmgakqkUlIZP8RLowxxiwN0vwexuOhoFZzZnBrObMas6AMtlcDr061x_aPXZ_I39UZeD1GbDR2bEPdnI-_uNEzbVq1qJ3Jw6zjF8eg4nO4-Sw8wFdMt3sH_7H-__ibvSTzy_-wCPGYT6EKWs2zERuwNytM15HzFhON5xXvwGgAZ9a</recordid><startdate>20111201</startdate><enddate>20111201</enddate><creator>Bassendine, Margaret F</creator><creator>Sheridan, David A</creator><creator>Felmlee, Daniel J</creator><creator>Bridge, Simon H</creator><creator>Toms, Geoffrey L</creator><creator>Neely, R. Dermot G</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20111201</creationdate><title>HCV and the hepatic lipid pathway as a potential treatment target</title><author>Bassendine, Margaret F ; Sheridan, David A ; Felmlee, Daniel J ; Bridge, Simon H ; Toms, Geoffrey L ; Neely, R. Dermot G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c550t-86c3c6c8313f689b24688b505c47fc0d3c6e40463b5f89512ab7e7e25bf8d0e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Apolipoproteins A - metabolism</topic><topic>Apolipoproteins B - metabolism</topic><topic>Apolipoproteins E - metabolism</topic><topic>Biological and medical sciences</topic><topic>Cholesterol</topic><topic>Chronic</topic><topic>Chylomicrons - metabolism</topic><topic>Gastroenterology and Hepatology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepacivirus - metabolism</topic><topic>Hepacivirus - pathogenicity</topic><topic>Hepatitis C</topic><topic>Hepatitis C - metabolism</topic><topic>Hepatitis C - therapy</topic><topic>Hepatitis C - virology</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Hypolipidemic Agents - therapeutic use</topic><topic>Infectious diseases</topic><topic>Lipid Metabolism - drug effects</topic><topic>Lipoproteins</topic><topic>Lipoproteins, VLDL - metabolism</topic><topic>Liver - metabolism</topic><topic>Medical sciences</topic><topic>Metabolic Networks and Pathways</topic><topic>Models, Biological</topic><topic>Pharmacology. Drug treatments</topic><topic>Triglycerides</topic><topic>Viral diseases</topic><topic>Viral hepatitis</topic><topic>VLDL</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bassendine, Margaret F</creatorcontrib><creatorcontrib>Sheridan, David A</creatorcontrib><creatorcontrib>Felmlee, Daniel J</creatorcontrib><creatorcontrib>Bridge, Simon H</creatorcontrib><creatorcontrib>Toms, Geoffrey L</creatorcontrib><creatorcontrib>Neely, R. Dermot G</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bassendine, Margaret F</au><au>Sheridan, David A</au><au>Felmlee, Daniel J</au><au>Bridge, Simon H</au><au>Toms, Geoffrey L</au><au>Neely, R. Dermot G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HCV and the hepatic lipid pathway as a potential treatment target</atitle><jtitle>Journal of hepatology</jtitle><addtitle>J Hepatol</addtitle><date>2011-12-01</date><risdate>2011</risdate><volume>55</volume><issue>6</issue><spage>1428</spage><epage>1440</epage><pages>1428-1440</pages><issn>0168-8278</issn><eissn>1600-0641</eissn><coden>JOHEEC</coden><abstract>Atherosclerosis has been described as a liver disease of the heart [1] . The liver is the central regulatory organ of lipid pathways but since dyslipidaemias are major contributors to cardiovascular disease and type 2 diabetes rather than liver disease, research in this area has not been a major focus for hepatologists. Virus–host interaction is a continuous co-evolutionary process [2] involving the host immune system and viral escape mechanisms [3] . One of the strategies HCV has adopted to escape immune clearance and establish persistent infection is to make use of hepatic lipid pathways. This review aims to: • update the hepatologist on lipid metabolism • review the evidence that HCV exploits hepatic lipid pathways to its advantage • discuss approaches to targeting host lipid pathways as adjunctive therapy.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>21718665</pmid><doi>10.1016/j.jhep.2011.06.004</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0168-8278 |
| ispartof | Journal of hepatology, 2011-12, Vol.55 (6), p.1428-1440 |
| issn | 0168-8278 1600-0641 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_905674350 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Apolipoproteins A - metabolism Apolipoproteins B - metabolism Apolipoproteins E - metabolism Biological and medical sciences Cholesterol Chronic Chylomicrons - metabolism Gastroenterology and Hepatology Gastroenterology. Liver. Pancreas. Abdomen Hepacivirus - metabolism Hepacivirus - pathogenicity Hepatitis C Hepatitis C - metabolism Hepatitis C - therapy Hepatitis C - virology Human viral diseases Humans Hypolipidemic Agents - therapeutic use Infectious diseases Lipid Metabolism - drug effects Lipoproteins Lipoproteins, VLDL - metabolism Liver - metabolism Medical sciences Metabolic Networks and Pathways Models, Biological Pharmacology. Drug treatments Triglycerides Viral diseases Viral hepatitis VLDL |
| title | HCV and the hepatic lipid pathway as a potential treatment target |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T23%3A33%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HCV%20and%20the%20hepatic%20lipid%20pathway%20as%20a%20potential%20treatment%20target&rft.jtitle=Journal%20of%20hepatology&rft.au=Bassendine,%20Margaret%20F&rft.date=2011-12-01&rft.volume=55&rft.issue=6&rft.spage=1428&rft.epage=1440&rft.pages=1428-1440&rft.issn=0168-8278&rft.eissn=1600-0641&rft.coden=JOHEEC&rft_id=info:doi/10.1016/j.jhep.2011.06.004&rft_dat=%3Cproquest_cross%3E905674350%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=905674350&rft_id=info:pmid/21718665&rft_els_id=S0168827811004922&rfr_iscdi=true |